 |
|
Experimental Drugs Take Aim at Obesity
Brian Vastag
JAMA. 2003;289:1763-1764.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Five years after the US Food and Drug Administration (FDA) banned the popular weight-loss drug fenfluramine after reports of heart-valve problems, three prescription weight-loss drugs remain on the US market. Just two are approved for long-term use. Phentermine, the first half of the infamous "Phen-Fen" combination, is still approved for short-term use.
In a nation of 60 million obese adults, the drug industry should be hungry to treat the condition. Yet, the Pharmaceutical Research and Manufacturers of America (PhRMA) lists only 11 new antiobesity drugs in clinical trials.
This trend has nothing to do with a lack of effort, according to researchers. Instead, the drought of drugs stems from obesity's complex nature. Only recently have researchers mapped the basic endocrinology of hunger and satiation, and many mysteries remain.
"It's been a long haul, and nothing much is around the corner," said Madelyn Fernstrom, PhD, director of the Weight . . . [Full Text of this Article]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist
van Oosten et al.
Mult Scler 2004;10:330-332.
ABSTRACT
Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats
Shklyaev et al.
Proc. Natl. Acad. Sci. USA 2003;100:14217-14222.
ABSTRACT
| FULL TEXT
Development of Novel Medications for Use in the Treatment of Obesity in Children Will Be Directed by Delineating Controls of Energy Homeostasis
Sherman and Zlotkin
Arch Pediatr Adolesc Med 2003;157:721-721.
FULL TEXT
|
